Concomitant Radio-chemotherapy in the Elderly
- Sponsor
- University Hospital, Limoges
- Study ID
- NCT01029678
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 70 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cisplatin IV — DRUGCisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
- Vinorelbine — DRUGVinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
- Radiotherapy — RADIATION66Gy, 33 fractions, 6 week
Study Details
The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.
Key Dates
- Start date
- Jan 31, 2010
- Status verified
- Jan 2018
- Primary completion
- Jan 31, 2015
- Completion
- Jun 30, 2016
Study Design
- Enrollment
- 48 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: experimental
Primary Outcome Measure
Acute toxicity [ Time Frame: during treatment and during the 4 weeks following the end of treatment ]
Related Studies
- The Effect of Beta-glucan in Non-Small Cell Lung CancerRecruiting · University of Louisville · Louisville, Kentucky
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of NEO-201 in Solid Tumors Expansion CohortsPHASE1/PHASE2 · Recruiting · Precision Biologics, Inc · Bethesda, Maryland